ArticleScientific reports2026
Microneedle patch-based delivery of Pyr-Apelin-13 reverses functional and structural deficits in age-related sarcopenia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, the age-associated loss of skeletal muscle mass and function, currently lacks effective pharmacological interventions. Pyr-Apelin-13, a potent endogenous peptide that stimulates mitochondrial biogenesis and myofiber regeneration, is limited by rapid plasma clearance and the need for frequent injections. We report the first preclinical evaluation of a transdermal Pyr-Apelin-13 microneedle (MN) patch (HeroPatch) in aged mice. The solid-state "drug-in-resin" design achieved near-complete release efficiency (≈100% in vitro; 83-99% in vivo), enabling reproducible multi-milligram delivery with minimal residual loss. Daily MN dosing significantly improved muscle fiber cross-sectional area and grip strength relative to controls, with outcomes comparable to daily intraperitoneal injection. Histological analysis revealed a shift toward larger fiber sizes, consistent with enhanced myofiber remodeling, and mitochondrial DNA content increased concordantly. Weekly dosing produced smaller, non-significant trends, reflecting lower cumulative exposure. These findings demonstrate that HeroPatch enables efficient, reproducible, and non-invasive systemic delivery of Apelin-13, providing a scalable platform for peptide-based therapy of sarcopenia and related muscle-wasting disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.